medicine-products/oxylab-ldf-4327-1/;msg18067;topicseen

Breaking Biology Technology:Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4 WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2 Alberta companies delivering new products to the health & medical marketplace 2 Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2 Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3 Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4

[0] Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A [0] WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening [0] Alberta companies delivering new products to the health & medical marketplace [0] Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe

Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2 ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3 ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4 VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 Qforma Appoints Erin McLaughlin as Director Field Operations 5834 1 Qforma Appoints Erin McLaughlin as Director Field Operations 5834 2 Webcast Alert 3A Transgenomic Inc Announces Third Quarter 2009 Earnings Release Conference Call Webcast 5832 1 Webcast Alert 3A Transgenomic Inc Announces Third Quarter 2009 Earnings Release Conference Call Webcast 5832 2 High Resolution Breast PET Improves Breast Cancer Detection 5830 1 High Resolution Breast PET Improves Breast Cancer Detection 5830 2 High Resolution Breast PET Improves Breast Cancer Detection 5830 3

[0] ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program [0] VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation [0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology